Recently, immunotherapy with Programmed Death Receptor-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) as checkpoints have been broadly adopted in LC's clinical treatment. This evidence concerns the gene CD274 and laryngotracheoesophageal cleft.